Project Grant R15HL175526
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$422K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Glendale, AZ 85308, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $644,687.00 to the University of Missouri System to study a critical forebrain-brainstem neural circuit that contributes to the adaptive and maladaptive cardiorespiratory responses to chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnea and other diseases. The research aims to resolve how this...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $744,305 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Rector & Visitors of the University of Virginia, doing business as the University of Virginia. The grant, which runs from April 4, 2025 to January 31, 2029, will fund research on the molecular physiology of PHOX2B-expressing respiratory chemoreceptor neurons in the retrotrapezoid nucleus (RTN) and their role in regulating breathing and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $605,678.00 to the University of South Alabama to conduct research on a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The research aims to explore the concept that a pathway called "BRACR" (Base Oxidation and Repair Activated Chromatin Restructuring) is a fundamental component of the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $151,578 over a 5-year period starting January 1, 2025 to conduct research on the impact of nocturnal hypoxemia (low oxygen saturation during sleep) on skeletal muscle protein homeostasis in chronic obstructive pulmonary disease (COPD) patients. The research aims to determine the role of the hypoxia-inducible factor 1-alpha...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant to the University of Arkansas under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The funding supports the development of microphysiological systems to study hypoxic cardiac injury resulting from acute myocardial infarction and ischemia-reperfusion injury. The research aims to engineer microfluidic devices to precisely control oxygen levels and investigate how oxygen...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) will provide $249,000.00 to the University of Wisconsin - Madison to support research led by Dr. Nicholas Burgraff. The research aims to unravel the mechanisms of opioid-induced airway constriction, with the goal of developing novel therapeutic strategies to improve patient safety and outcomes in medical scenarios where opioids are...
This Project Grant award of $696,470 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to investigate how prenatal maternal sleep patterns influence pathways to cardiovascular disease risk in children. The project aims to examine three key pathways: maternal biological processes (stress and inflammation), child biological processes (growth and adiposity), and child behavior (sleep, emotionality,...
This federal Project Grant award of $332,862.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, will support research to assess night-to-night variability in novel sleep disordered breathing severity metrics and their impact on daytime functioning. The study aims to characterize reliable biomarkers of obstructive sleep apnea (OSA) severity, as the current standard measure (Apnea-Hypopnea Index) underestimates...
This federal Project Grant award, valued at $564,445.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, effective March 1, 2025 through December 31, 2031, supports the University of Texas Health Science Center at Houston's "Hypoxia-Inflammation Program" research focused on targeting hypoxia-inducible factors (HIFs) for the treatment of heart and lung diseases. The funded...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $711,226 to the University of California, Los Angeles (UCLA) to conduct research on the impacts of obstructive sleep apnea (OSA) on the brain. The objectives are to: 1) examine regional brain temperatures in OSA patients compared to controls; 2) assess whole-brain metabolite and antioxidant levels in OSA and controls; 3)...